KYMR Kymera Therapeutics Inc

$66.04

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Kymera Therapeutics, with a market cap of approximately $3.26 billion, is poised to release its earnings on August 1, 2025, amid a backdrop of anticipation for its innovative protein degradation technology. The company's strategic focus on advancing its pipeline of targeted therapies has captured investor interest, even as the EPS estimate and whisper number both stand at $0.00, reflecting the early-stage nature of its operations. Analysts are eyeing the revenue estimate of $22.24 million as a key indicator of progress in monetizing its groundbreaking research. With no recent news to sway market sentiment, the upcoming earnings report will be crucial in assessing Kymera's trajectory and its ability to translate scientific advancements into financial performance.

Updated On 11/21/2025

About Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.

Website: https://www.kymeratx.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1815442
Address
300 TECHNOLOGY SQUARE, 2ND FLOOR, CAMBRIDGE, MA, US
Valuation
Market Cap
$1.69B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
2.02
Performance
EPS
$-2.98
Dividend Yield
—
Profit Margin
0.00%
ROE
-36.40%
Technicals
50D MA
$31.25
200D MA
$40.93
52W High
$53.27
52W Low
$19.45
Fundamentals
Shares Outstanding
65M
Target Price
$57.67
Beta
2.23

KYMR EPS Estimates vs Actual

● Estimated
● Actual

KYMR News & Sentiment

Nov 04, 2025 • Zacks Commentary NEUTRAL
Kymera Therapeutics, Inc. ( KYMR ) Reports Q3 Loss, Misses Revenue Estimates
Kymera Therapeutics (KYMR) delivered earnings and revenue surprises of -26.76% and -89.60%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 03, 2025 • GlobeNewswire NEUTRAL
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
WATERTOWN, Mass., Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside ...
Oct 28, 2025 • GlobeNewswire NEUTRAL
Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025
WATERTOWN, Mass., Oct. 28, 2025 ( GLOBE NEWSWIRE ) -- Kymera Therapeutics, Inc. ( NASDAQ: KYMR ) , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November ...
Oct 27, 2025 • Zacks Commentary NEUTRAL
TG Therapeutics ( TGTX ) Earnings Expected to Grow: What to Know Ahead of Q3 Release
TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 27, 2025 • Benzinga NEUTRAL
Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting - Kymera Therapeutics ( NASDAQ:KYMR )
KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis ( RA ) , with activity comparable or superior to approved and clinically active therapies KT-579 Phase 1 testing expected to begin in early 2026
Oct 23, 2025 • Zacks Commentary NEUTRAL
Kymera Therapeutics, Inc. ( KYMR ) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Kymera Therapeutics (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sentiment Snapshot

Average Sentiment Score:

0.117
50 articles with scored sentiment

Overall Sentiment:

Neutral

KYMR Reported Earnings

Aug 11, 2025
Jun 30, 2025 (Pre market)
-0.12 Surprise
  • Reported EPS: $-0.95
  • Estimate: $-0.83
  • Whisper: —
  • Surprise %: -14.5%
May 09, 2025
Mar 31, 2025 (Pre market)
-0.09 Surprise
  • Reported EPS: $-0.82
  • Estimate: $-0.73
  • Whisper: —
  • Surprise %: -12.3%
Feb 27, 2025
Dec 31, 2024 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.89
  • Estimate: $-0.79
  • Whisper: —
  • Surprise %: -12.9%
Oct 31, 2024
Sep 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.82
  • Estimate: $-0.84
  • Whisper: —
  • Surprise %: 2.4%
Aug 07, 2024
Jun 30, 2024 (Pre market)
0.1 Surprise
  • Reported EPS: $-0.58
  • Estimate: $-0.68
  • Whisper: —
  • Surprise %: 14.7%
May 02, 2024
Mar 31, 2024 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.62
  • Estimate: $-0.73
  • Whisper: —
  • Surprise %: 15.1%
Feb 22, 2024
Dec 31, 2023 (Pre market)
0.15 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: 37.5%
Nov 02, 2023
Sep 30, 2023 (Pre market)
-0.26 Surprise
  • Reported EPS: $-0.90
  • Estimate: $-0.64
  • Whisper: —
  • Surprise %: -40.6%
Aug 03, 2023
Jun 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.67
  • Estimate: $-0.71
  • Whisper: —
  • Surprise %: 5.6%

Financials